Puma Biotechnology, Inc. (PBYI) Stock Price & Analysis
Puma Biotechnology, Inc. (PBYI) fell 0.37% to USD 7.98 as of July 25, 2026 at 03:04 UTC, according to Nexqual real-time market data.
PBYI last closed at USD 8.01; the session ranged USD 7.94–8.11 on volume of 193,530 shares. Market capitalization is $406.18M, with a 52-week range of USD 3.03–8.75 (NMS). Source: Nexqual, July 25, 2026 at 03:04 UTC.
Key Statistics (as of July 25, 2026 at 03:04 UTC)
| Price | USD 7.98 |
|---|---|
| Change | ▼ 0.37% (down) |
| Previous Close | USD 8.01 |
| Open | USD 8.05 |
| Day Range | USD 7.94 – 8.11 |
| 52-Week Range | USD 3.03 – 8.75 |
| Volume | 193,530 shares |
| Market Cap | $406.18M |
| Exchange | NMS |
Technical Analysis (PBYI)
Nexqual's technical model rates PBYI "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 03:04 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 51.32 (neutral) |
| vs SMA50 | Above (USD 7.58) |
| MACD | 0.15 (positive) |
Analyst Ratings (PBYI)
Wall Street analysts rate PBYI "None" based on 1 analysts, with a mean price target of USD 5 (range USD 5–5), per Nexqual as of July 25, 2026 at 03:04 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 5 |
| High Target | USD 5 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 0 / 1 / 0 |
Earnings (PBYI)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 0.07 |
| Revenue Estimate | $53.00M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.04 vs est -0.13 ▲ beat |
| 2025-12-31 | USD 0.29 vs est 0.23 ▲ beat |
| 2025-09-30 | USD 0.21 vs est 0.09 ▲ beat |
| 2025-06-30 | USD 0.15 vs est 0.07 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
Financials & Fundamentals (PBYI)
| Total Revenue | $227.18M |
|---|---|
| Revenue Growth (YoY) | -2.60% |
| Gross Margin | +74.46% |
| Operating Margin | -8.54% |
| Profit Margin | +10.73% |
| ROE | +21.62% |
| Debt / Equity | 12.42 |
| Current Ratio | 2.38 |
| Total Cash | $101.55M |
| Total Debt | $15.95M |
| Free Cash Flow | $44.09M |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
Financial Health Score (PBYI)
Nexqual rates Puma Biotechnology, Inc.'s overall financial health "Solid" across five dimensions, as of July 25, 2026 at 03:04 UTC.
| Growth | Weak — Revenue -1% YoY (annual), declining |
|---|---|
| Profitability | Solid — Gross margin 74%, operating -9% |
| Balance Sheet | Strong — $102M cash vs $16M debt, net cash position |
| Cash Flow | Strong — FCF $44M, 19% margin |
| Efficiency | Strong — ROE 22%, ROA 9.5% |
Ownership (PBYI)
| Insider Ownership | +15.49% |
|---|---|
| Institutional Ownership | +74.99% |
| Shares Outstanding | 50.90M |
| Float | 38.90M |
| Short % of Float | +8.37% |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
Leadership (PBYI)
Puma Biotechnology, Inc. is led by Alan H. Auerbach (age 55), Founder, Chairman, President, CEO & Secretary, per Nexqual as of July 25, 2026 at 03:04 UTC.
| Founder, Chairman, President, CEO & Secretary | Alan H. Auerbach (age 55) |
|---|---|
| CFO & Principal Accounting Officer | Maximo F. Nougues (age 56) |
| Senior Director of Investor Relations | Mariann Ohanesian |
| Senior Vice President of Marketing | Heather Blaber |
| Senior Vice President of Sales | Roger L. Storms |
Major Backers & Investors (PBYI)
Notable institutional backers of Puma Biotechnology, Inc. include Acorn Capital Advisors, LLC , American Century Companies Inc, Acadian Asset Management. LLC, according to Nexqual as of July 25, 2026 at 03:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Acorn Capital Advisors, LLC | 8.12% |
| American Century Companies Inc | 7.8% |
| Acadian Asset Management. LLC | 4.01% |
| Renaissance Technologies | 3.82% |
| Millennium Management | 2.9% |
| LSV Asset Management | 2.32% |
| Fidelity | 0.84% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 13.04% |
| BlackRock | 9.88% |
| Dimensional Fund Advisors | 2.82% |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
From Puma Biotechnology, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Partnerships
- We are currently party to several sub-licenses in various regions outside the United States, including Europe (excluding Ukraine), Australia, Canada, China, Southeast Asia, Israel, South Korea, Russia and various countries and territories in Central America, South America, Africa and the Middle East.   Alisertib   In September 2022, we entered into an exclusive license agreement with Takeda to license the worldwide research and development and commercial rights to alisertib.
- In February 2013, we reached agreement with the FDA under a Special Protocol Assessment ("SPA") for our Phase III clinical trial (PUMA-NER-1301 or the NALA trial) of neratinib in patients with HER2-positive metastatic breast cancer who have failed two or more prior treatments (third-line disease).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AGIO | Agios Pharmaceuticals, Inc. | USD 36.36 | ▲ 0.86% |
| PTCT | PTC Therapeutics, Inc. | USD 76.82 | ▼ 2.02% |
| KPTI | Karyopharm Therapeutics Inc. | USD 7.41 | ▲ 3.2% |
| RARE | Ultragenyx Pharmaceutical Inc. | USD 26.9 | ▼ 2.69% |
| MGNX | MacroGenics, Inc. | USD 3.7 | ▼ 13.95% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:04 UTC. This page is informational and not investment advice.